Edition:
United Kingdom

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

9,054JPY
3:55am GMT
Change (% chg)

¥-67 (-0.73%)
Prev Close
¥9,121
Open
¥9,142
Day's High
¥9,142
Day's Low
¥8,994
Volume
193,000
Avg. Vol
815,199
52-wk High
¥11,490
52-wk Low
¥6,554

Chart for

About

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's business segments include pharmaceutical segment and other segment. The pharmaceutical segment is engaged in the research, develop, manufacture and sale of pharmaceuticals for medical use, generic... (more)

Overall

Beta: 0.68
Market Cap(Mil.): ¥1,746,483.00
Shares Outstanding(Mil.): 296.57
Dividend: 80.00
Yield (%): 2.55

Financials

  4523.T Industry Sector
P/E (TTM): 57.32 29.30 32.54
EPS (TTM): 102.73 -- --
ROI: 4.05 14.23 13.82
ROE: 5.24 15.46 15.25

Eisai, Biogen Alzheimer's data fails to convince skeptics

Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

25 Oct 2018

UPDATE 2-Eisai, Biogen Alzheimer's data fails to convince skeptics

Oct 25 Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

25 Oct 2018

UPDATE 1-Biogen shares slip after Alzheimer's data fails to convince

Oct 25 Biogen Inc and partner Eisai Co Ltd said on Thursday the highest dose of its experimental Alzheimer's drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data.

25 Oct 2018

Biogen/Eisai Alzheimer's data suggests treatment effect related to drug

Oct 25 Biogen and partner Eisai Co Ltd said data from their experimental Alzheimer's drug suggested that the treatment effect for the highest dose was related to the drug, and not to an imbalance of patients in the treatment groups.

25 Oct 2018

Earnings vs. Estimates